Physician profile
Kyle C Harner
NPI 1073547931
$8,176.81
in general payments reported to CMS, 2019-2025
31 companies · $553 in 2025
The $553 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,976 · 2020: $761 · 2021: $687 · 2022: $1,467 · 2023: $1,605 · 2024: $1,127 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,231 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,230.63 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,269.01 | 2019-2025 | Otezla, Enbrel, Tavneos |
| Abbvie INC. | $1,166.36 | 2019-2025 | |
| Horizon Therapeutics Plc | $755.64 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $684.81 | 2019-2025 | Zepbound, Taltz, Olumiant |
| Janssen Biotech, INC. | $614.99 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $588.73 | 2019-2024 | Bimzelx |
| Glaxosmithkline, LLC. | $445.30 | 2019-2024 | Benlysta |
| Pfizer INC. | $404.04 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $387.76 | 2019-2023 | Orencia |
| Astrazeneca Pharmaceuticals LP | $294.08 | 2021-2024 | Saphnelo |
| Celgene Corporation | $223.55 | 2019 | |
| Genzyme Corporation | $186.83 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $179.68 | 2019-2024 | |
| Ani Pharmaceuticals, INC. | $142.37 | 2023 | Purified Cortrophin Gel |
| Janssen Scientific Affairs, LLC | $99.99 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $97.10 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Hikma Pharmaceuticals USA | $95.96 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $95.01 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.46 | 2019-2024 | Cyltezo |
| Genentech USA, INC. | $72.72 | 2019 | |
| Merck Sharp & Dohme LLC | $55.81 | 2019-2020 | |
| Organon LLC | $48.01 | 2021-2024 | |
| Sandoz INC. | $32.64 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $23.93 | 2023 | Uptravi, Opsumit |
| Octapharma USA, INC. | $23.39 | 2025 | Octagam Immune Globulin (Human) |
| Aurinia Pharma U.S., INC. | $21.12 | 2024 | Lupkynis |
| Kowa Pharmaceuticals America, INC. | $20.62 | 2023 | Seglentis |
| Arbor Pharmaceuticals, INC. | $18.18 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.82 | 2019 | |
| Mallinckrodt Enterprises LLC | $15.57 | 2019 | |
| Medexus Pharma, INC. | $14.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Harner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.